2 results
Approved WMOWill not start
The primary objective of this study is to assess tolerance and efficacy of 12 weeks BP1.3656 (30 µg or 60 µg OD versus placebo) to reduce alcohol consumption in alcohol dependent patients.
Approved WMOPending
The BeyeOMARKER study*s primary aim is to (1) provide proof-of-concept for blood-based biomarkers as a tool for minimally invasive early detection of AD pathology in a diverse population from an alternative clinically relevant setting. Secondly, we…